In 2023, South Korea, Greece, and Spain witnessed varied trends in Renin-Angiotensin System Medicine Sales per Capita with values of $39, $34.5, and $34.1 respectively. South Korea saw a 5.67% YoY increase, while Greece faced a decline of 7.23%. Spain had a modest rise of 3.8%. Additionally, New Zealand showed significant growth at 19.83%, and Denmark at 8.89%. These trends reflect differing regional demand and healthcare investments.
Future Trends
Future trends indicate potential volatility in markets such as Greece and Canada, with healthcare policy changes and economic factors playing pivotal roles. Emerging advancements in personalized medicine and regional health initiatives will likely influence sales dynamics, making it crucial to monitor healthcare reforms and economic conditions closely.
Top countries in Renin-Angiotensin System Medicine Sales by Country
# | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
---|---|---|---|---|---|---|
1 | 1 South Korea | 39 | 2023 | +3.72% | +5.67% | View data |
2 | 2 Greece | 34.5 | 2023 | -5.22% | -7.23% | View data |
3 | 3 Spain | 34.1 | 2023 | +3.02% | +3.8% | View data |
4 | 4 Germany | 32.3 | 2023 | +1.57% | +3.2% | View data |
5 | 5 Hungary | 28.4 | 2023 | 0% | -0.14% | View data |
6 | 6 Canada | 18.8 | 2023 | -9.62% | -4.36% | View data |
7 | 7 Austria | 18.6 | 2023 | -3.12% | -4.07% | View data |
8 | 8 Chile | 10.4 | 2023 | 0% | +6.47% | View data |
9 | 9 Sweden | 9.4 | 2023 | +6.82% | +8.68% | View data |
10 | 10 Norway | 9.3 | 2023 | -4.12% | 0% | View data |